Company news

Puretech Health Plc (LSE:PRTC) news

Puretech Health Plc news releases on 6ix. Latest, Sep 21, 2026: PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration…

Puretech Health Plc (LSE:PRTC) news

Press releases & updates

PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)

PRTC's SPTX: New Positive Phase 1 GlyphAllo Data

PRTC's Celea:2 Deupirfenidone Presentations at ERS

PRTC: Celea Doses 1st Patient in Phase 3 IPF Trial

PRTC Launches Celea w/ $180M & Top Tier Syndicate

PRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data

Correction - Holding(s) in Company

PRTC To Showcase Deupirfenidone at ATS Conference

PureTech's Seaport Prices Upsized IPO Nasdaq: SPTX

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

PRTC's Seaport Adds Neuropsychiatry Veteran to BOD

PRTC's Gallop: Positive Ph1 Topline MDS & AML Data

PRTC's Seaport Files for Proposed Nasdaq IPO

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

PRTC’s Seaport: GlyphAllo Paper Published

PDMR Notification RSU Vesting

Total Voting Rights

PRTC to Present at Leerink Healthcare Conference

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

PRTC's Deupirfenidone Granted FDA & EU ODD for IPF

PureTech to Present at the JP Morgan Conference

PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference

PureTech Appoints Robert Lyne as Chief Executive Officer

PureTech Appoints Robert Lyne as CEO

Results of AGM on June 16, 2025 – Update Statement

Holding(s) in Company

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

PRTC: Successful FDA Meeting; IPF Phase 3 in 1H26

PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

PRTC's Gallop: Positive Initial Topline AML Data

PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting

PRTC: New LYT-200 AML Data + Update at ASH

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

PRTC: New IPF Data Show Benefit in Older Patients

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

PRTC: New IPF Data Show Switch Patients Stabilized

PDMR DEALING - PURCHASE OF SHARES

PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers

PRTC's Seaport Advances 2nd Candidate Into Clinic

PureTech Health plc – Half-Year Report

Half-year Report

PureTech Showcases Differentiated IPF Strategy

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

PureTech Health: Notice of Half-Yearly Results

Notice of Results

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

PRTC's Vedanta Announces VE202 Phase 2 Results

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases